July 16, 2012 / 3:31 PM / 5 years ago

UPDATE 1-Repros to submit trial design for oral Proellex

* FDA may update status on drug to “partial clinical hold”

* Co to submit the study design in a few days

July 16 (Reuters) - Repros Therapeutics Inc said it will submit to regulators in the next few days a design for a mid-stage trial of an oral version of its tumor drug, Proellex, that could lead to a partial lift of a clinical hold.

The U.S. Food and Drug Administration asked Repros in May to submit safety data from a completed mid-stage trial on the drug. The FDA put a clinical hold on oral Proellex in 2009 due to liver toxicity issues associated with high doses.

In the planned mid-stage trial, doses of 6 and 12 mg will be tested using accepted pain endpoints, the company said in a statement.

Repros is testing Proellex to treat symptoms of uterine fibroids, or non-cancerous tumors in the womb, and endometriosis, a disorder that can lead to infertility in women.

Shares in the Woodlands, Texas-based company were up 5 percent at $8.50 on the Nasdaq.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below